EA90 - Psoriasis: Complete ICD-11 Coding Guide

1. Introduction

Psoriasis represents one of the most prevalent and complex dermatological conditions in contemporary medical practice. This chronic inflammatory skin disease affects approximately 2% of the global population, manifesting through characteristic cutaneous lesions that significantly impact patients' quality of life. Unlike transient dermatological conditions, psoriasis presents a recurrent and persistent course, requiring continuous medical follow-up and individualized therapeutic strategies.

The clinical importance of psoriasis transcends visible cutaneous manifestations. This condition has a strong genetic component and is closely associated with serious systemic comorbidities, including psoriatic arthritis, metabolic syndrome, cardiovascular diseases, and psychological disorders. Studies demonstrate that up to 20% of patients develop psoriatic arthritis, an inflammatory polyarthritis that can cause permanent joint deformities and significant functional impairment.

From a public health perspective, psoriasis represents a considerable challenge. Direct costs related to treatment, combined with indirect costs resulting from work absenteeism and reduced productivity, generate substantial economic impact on health systems globally. Furthermore, the social stigma associated with visible lesions frequently results in social isolation, depression, and anxiety, further compromising patients' well-being.

Appropriate coding of psoriasis using the ICD-11 system is fundamental to ensure accurate clinical documentation, facilitate epidemiological research, enable cost-effectiveness analyses of treatments, and assure appropriate reimbursement by health systems. The transition from ICD-10 to ICD-11 brought important refinements in the classification of dermatoses, making it essential that health professionals understand the specificities of code EA90 and its clinical applications.

2. Correct ICD-11 Code

Code: EA90

Description: Psoriasis

Parent category: Papulosquamous dermatosis

Official definition: Psoriasis is a common, chronic, recurrent inflammatory disorder of the skin, characterized by an abnormality in keratinization and epidermal hyperproliferation. It has a strong genetic component and affects approximately 2% of populations in many regions of the world. Up to 10-20% of patients with psoriasis also present with inflammatory polyarthritis (psoriatic arthritis). Although many people with psoriasis have limited disease, both psoriasis and associated arthritis generally cause significant functional and psychosocial disability. The more severe forms of psoriasis are frequently associated with metabolic syndrome and, consequently, with reduced life expectancy.

The code EA90 belongs to the chapter of skin diseases in the ICD-11 classification, specifically within the group of papulosquamous dermatoses. This category encompasses conditions characterized by papules and skin scaling, but psoriasis stands out for its unique histopathological characteristics, specific distribution pattern, and particular clinical course. The hierarchical structure of ICD-11 allows greater specificity through subcategories that detail the different clinical types of psoriasis, facilitating accurate documentation of each patient's individual presentation.

3. When to Use This Code

The code EA90 should be used in specific clinical situations where the diagnosis of psoriasis has been established through clinical criteria and, when necessary, histopathological confirmation. Below, we present detailed practical scenarios:

Scenario 1: Plaque psoriasis vulgaris A 35-year-old patient presents with well-demarcated erythematous-scaly lesions, with thick silvery scales, located on the elbows, knees, and lumbosacral region. The lesions are symmetric, pruritic, and have persisted for more than six months. Dermoscopic examination reveals dilated capillary vessels distributed uniformly. This is the classic scenario that justifies the use of code EA90, representing the most common form of disease presentation.

Scenario 2: Post-infectious guttate psoriasis An adolescent develops sudden eruption of small erythematous-scaly lesions in a drop-like pattern, distributed across the trunk and limbs, two weeks after an episode of streptococcal pharyngitis. The history of preceding infection and the characteristic morphological pattern confirm the diagnosis of guttate psoriasis, which should be coded with EA90, and may include additional specifiers for the subtype.

Scenario 3: Scalp psoriasis A patient reports intense and persistent scaling of the scalp, with well-demarcated erythematous plaques that extend beyond the hairline. The scales are thick, adherent, and silvery, clearly differentiating from seborrheic dermatitis. Concomitant nail involvement (punctate depressions and onycholysis) reinforces the diagnosis of psoriasis, justifying code EA90.

Scenario 4: Palmoplantar psoriasis A patient presents with painful fissured hyperkeratosis on the palms and soles, with underlying erythema and characteristic scaling. The lesions are symmetric and cause significant functional limitation for manual activities and ambulation. Skin biopsy confirms epidermal hyperproliferation with Munro microabscesses, definitively establishing the diagnosis of palmoplantar psoriasis under code EA90.

Scenario 5: Inverse or flexural psoriasis A patient with well-demarcated, shiny erythematous lesions with minimal scaling, located in intertriginous areas (armpits, inguinal region, inframammary and intergluteal areas). Despite the atypical presentation without classic silvery scales, the distribution pattern, chronicity, and absence of secondary infection confirm inverse psoriasis, appropriately coded as EA90.

Scenario 6: Psoriasis with isolated nail involvement A patient presents with characteristic nail changes including pitting, onycholysis, subungual hyperkeratosis, and oil spots without evident cutaneous lesions at the time of evaluation. The positive family history for psoriasis and the specific characteristics of the nail changes justify the diagnosis of nail psoriasis, coded with EA90.

4. When NOT to Use This Code

It is fundamental to recognize situations where code EA90 should not be applied, avoiding coding errors that compromise medical records and epidemiological statistics:

Seborrheic dermatitis: Although it may present with scaling and erythema in similar areas (scalp, centrofacial region), seborrheic dermatitis is characterized by yellowish and oily scales, not silvery and dry as in psoriasis. The preferential distribution in seborrheic areas and the response to topical antifungals differentiate this condition, which requires a specific code different from EA90.

Nummular eczema: Presents with circular or oval lesions with scaling, but differs from psoriasis by the presence of vesiculation, exudation and crusts, in addition to more intense pruritus. Histopathology shows characteristic spongiosis of eczema, absent in psoriasis.

Tinea corporis: Annular lesions with scaling may mimic psoriasis, but the presence of an active border with central clearing, positive mycological examination and response to antifungals confirm fungal infection, and should not be coded as EA90.

Pityriasis rosea: A self-limited condition that may begin with a herald patch followed by secondary eruption in a "Christmas tree" pattern. Spontaneous resolution in weeks and characteristic distribution differentiate it from chronic psoriasis.

Lichen planus: Although it is a papulosquamous dermatosis, it presents with violaceous polygonal papules with Wickham's striae, morphology and course distinct from psoriasis, requiring code EA91.

Drug reactions: Psoriasiform eruptions induced by medications (beta-blockers, lithium, antimalarials) should be coded as adverse drug reactions, not as primary psoriasis.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The diagnosis of psoriasis is based primarily on clinical criteria. The examiner must identify well-demarcated erythematous-scaly lesions with characteristic silvery scales that, when removed, reveal hemorrhagic points (Auspitz sign). Symmetric distribution in extension areas (elbows, knees), scalp, and lumbosacral region is typical.

Dermoscopy aids in identifying dilated capillaries uniformly distributed over an erythematous background. In atypical cases or when diagnostic doubt exists, skin biopsy is fundamental, revealing regular acanthosis, elongation of dermal papillae, hyperkeratosis and parakeratosis, in addition to characteristic inflammatory infiltrate with neutrophils forming Munro microabscesses.

The evaluation should include detailed history investigating family history, triggering factors (stress, infections, skin trauma), medications in use, and articular symptoms. Complete physical examination should document extent of skin involvement, distribution pattern, and nail alterations.

Step 2: Verify specifiers

After confirming the diagnosis of psoriasis, it is essential to determine the clinical subtype, as ICD-11 offers specific subcategories. The main subtypes include vulgar plaque psoriasis (most common), guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, and inverse psoriasis.

Severity should be evaluated considering extent of affected body surface area, functional impact, and location. Tools such as PASI (Psoriasis Area and Severity Index) and DLQI (Dermatology Life Quality Index) objectively quantify severity and impact on quality of life, valuable information for clinical documentation.

Disease duration (acute, subacute, or chronic) and evolutionary pattern (stable, progressive, or in remission) should be documented. The presence of associated comorbidities, especially psoriatic arthritis, metabolic syndrome, and psychological disorders, should be investigated and coded separately when present.

Step 3: Differentiate from other codes

EA91 - Lichen planus: Differentiated by lesion morphology (violaceous polygonal papules versus erythematous-scaly plaques), presence of Wickham striae on lesion surface, preferential mucosal involvement, and distinct histopathological pattern with hydropic degeneration of the basal layer. Lichen planus tends to be more pruritic and presents less pronounced Koebner phenomenon.

EA92 - Lichenoid dermatoses: This code encompasses conditions that present lichenoid pattern without meeting criteria for classic lichen planus or psoriasis. Includes drug-induced lichenoid reactions and atypical variants. Differentiation requires careful analysis of clinical context, medication exposure, and specific histopathological features.

EA93 - Pityriasis lichenoides: Characterized by papular eruption with episodic evolution, presenting lesions in different evolutionary stages simultaneously. Individual lesions tend to present central necrosis and hemorrhagic crusts, characteristics absent in psoriasis. Histopathology shows characteristic lichenoid vasculitis, clearly differentiating it from psoriasis.

Step 4: Required documentation

Adequate documentation should include:

Mandatory checklist:

Detailed description of lesions (morphology, color, texture, borders)
Precise anatomical location and distribution pattern
Extent of involvement (percentage of body surface area)
Presence or absence of nail alterations
Associated symptoms (pruritus, pain, bleeding)
Duration of symptoms and evolutionary pattern
Family history of psoriasis or autoimmune diseases
Identified triggering factors
Previous treatments and therapeutic responses
Associated comorbidities
Functional and psychosocial impact
Results of skin biopsy when performed
Clinical photographs when available
Severity scores (PASI, BSA, DLQI)

6. Complete Practical Example

Clinical Case:

A 42-year-old male patient consulted a dermatologist reporting persistent skin lesions for eight months. He reports that the lesions started as small reddish spots on the elbows, which progressively increased in size and spread to the knees, lumbar region, and scalp. He reports intense scaling, especially on the scalp, and moderate pruritus on the lesions. He denies fever, malaise, or systemic symptoms.

Family history reveals that the father had similar "skin spots." The patient identifies a period of intense work-related stress preceding the appearance of the lesions. He denies regular medication use. He reports attempting treatment with moisturizers and anti-dandruff shampoos without significant improvement.

On dermatological physical examination, multiple well-demarcated erythematoscaly plaques are observed, with sizes varying between 2 and 8 centimeters in diameter. The lesions present thick, adherent silvery scales. Symmetric distribution on bilateral elbows, knees, lumbosacral region, and scalp. When attempting to remove the scales, hemorrhagic points are evident (positive Auspitz sign). The estimated involvement is approximately 15% of body surface area.

Nail examination reveals punctate depressions (pitting) in six fingernails and discrete onycholysis in two toenails. Absence of mucosal involvement. Joint examination without significant alterations, without signs of active arthritis.

Dermoscopy was performed demonstrating dilated capillary vessels uniformly distributed over an erythematous base. A biopsy of the lesion on the left elbow was chosen, whose histopathological result revealed: regular acanthosis with elongation of dermal papillae, hyperkeratosis with focal parakeratosis, Munro microabscesses in the corneal layer, and perivascular lymphocytic inflammatory infiltrate in the superficial dermis.

Step-by-Step Coding:

Analysis of criteria:

Well-demarcated erythematoscaly lesions with silvery scales: PRESENT
Symmetric distribution in typical areas (elbows, knees, lumbar): PRESENT
Positive Auspitz sign: PRESENT
Characteristic nail alterations: PRESENT
Chronicity (more than 6 months): PRESENT
Positive family history: PRESENT
Histopathological confirmation: PRESENT

Code chosen: EA90 - Psoriasis

Complete justification: The diagnosis of psoriasis is established based on characteristic clinical presentation, including well-demarcated erythematoscaly plaques with silvery scales in typical distribution, positive Auspitz sign, and compatible nail alterations. Histopathological confirmation demonstrated classic findings of psoriasis, including regular acanthosis, parakeratosis, and Munro microabscesses. The positive family history and chronicity of the lesions reinforce the diagnosis.

Applicable complementary codes:

Specific subcategory of clinical type (plaque psoriasis vulgaris)
Code for moderate severity based on involvement of 15% of body surface area
Z code for family history of psoriasis when relevant for documentation

7. Related Codes and Differentiation

Within the Same Category:

EA91: Lichen planus

When to use vs. EA90: Use EA91 when lesions present with violaceous polygonal papules with visible Wickham striae, especially with oral or genital mucosal involvement. Lichen planus presents with more intense pruritus and histopathological pattern with hydropic degeneration of the basal layer.
Main difference: Morphology of lesions (violaceous polygonal papules versus erythematous scaly plaques), presence of Wickham striae and pattern of frequent mucosal involvement in lichen planus.

EA92: Lichenoid dermatoses

When to use vs. EA90: Apply EA92 for conditions with lichenoid pattern that do not meet criteria for classic lichen planus nor for psoriasis, including drug-induced lichenoid reactions or atypical variants without specific classification.
Main difference: Heterogeneous and frequently reactive nature of lichenoid dermatoses, versus primary and genetically determined nature of psoriasis.

EA93: Pityriasis lichenoides

When to use vs. EA90: Use EA93 when there is polymorphic papular eruption with lesions in different evolutionary stages, presence of central necrosis and hemorrhagic crusts, course in flares with spontaneous resolution of individual lesions.
Main difference: Course in flares with polymorphic lesions and central necrosis versus persistent and stable plaques of psoriasis; histopathology showing lichenoid vasculitis versus epidermal hyperproliferation.

Differential Diagnoses:

Seborrheic dermatitis is frequently confused with scalp psoriasis, but presents with yellowish oily scales instead of dry silvery ones, distribution in seborrheic areas and response to antifungals.

Nummular eczema may present with circular scaly lesions, but is characterized by vesiculation, exudation and more intense pruritus, with histopathology showing spongiosis.

Pityriasis rosea begins with a herald patch followed by secondary eruption in a "Christmas tree" pattern, being self-limited in weeks, unlike the chronicity of psoriasis.

8. Differences with ICD-10

In the ICD-10 system, psoriasis was coded primarily as L40, with subdivisions for different clinical types (L40.0 for psoriasis vulgaris, L40.1 for generalized pustular psoriasis, L40.5 for psoriatic arthritis, among others). The L40 code remained relatively broad, with limited specificity for less common clinical variants.

The transition to ICD-11 with code EA90 brought significant refinements to the coding structure. The ICD-11 system offers greater granularity through post-coordinated extensions that allow specification of anatomical location, severity, temporal pattern, and specific characteristics without the need for multiple separate codes. This modular approach facilitates more precise and detailed documentation.

An important change concerns psoriatic arthritis, which in ICD-11 has more integrated classification between the dermatology and rheumatology chapters, allowing better documentation of the systemic nature of the disease. ICD-11 also explicitly incorporates the association with metabolic syndrome in the official definition, reflecting contemporary understanding of psoriasis as a systemic disease.

The practical impact of these changes includes improved epidemiological traceability, facilitation of international multicenter research, greater precision in cost-effectiveness analyses, and potential for more appropriate reimbursements based on documented severity and complexity. Healthcare professionals should familiarize themselves with the ICD-11 structure to fully leverage its expanded clinical documentation capabilities.

9. Frequently Asked Questions

How is psoriasis diagnosed? The diagnosis is primarily clinical, based on the identification of characteristic erythematous-scaly lesions with silvery scales, typical distribution in areas of extension and scalp, and positive Auspitz sign. Dermoscopy aids in demonstrating uniformly distributed dilated capillary vessels. In atypical cases or when diagnostic doubt exists, skin biopsy confirms the diagnosis by revealing epidermal hyperproliferation, parakeratosis, and Munro microabscesses. Complete evaluation includes family history, identification of triggering factors, and investigation of associated comorbidities.

Is treatment available in public health systems? Most public health systems offer treatments for psoriasis, although the availability of specific therapies varies according to local resources and institutional protocols. Topical treatments with corticosteroids, vitamin D analogs, and keratolytics are generally widely available. Narrow-band UVB phototherapy is offered in specialized centers. Traditional systemic medications such as methotrexate and acitretin are usually accessible. Modern biologic therapies may have more restricted availability, often reserved for severe cases refractory to conventional treatments, through careful evaluation and clinical justification.

How long does treatment last? Psoriasis is a chronic condition without definitive cure, requiring long-term maintenance treatment. The duration of initial active treatment varies according to severity and therapeutic response, typically between 8 and 16 weeks to achieve adequate control. After achieving significant improvement, many patients require continuous or intermittent maintenance therapy to prevent relapses. Some patients experience periods of spontaneous remission ranging from months to years, while others require uninterrupted treatment. Regular dermatological follow-up is essential to adjust therapies according to clinical evolution and monitor medication adverse effects.

Can this code be used in medical certificates? Yes, the code EA90 can and should be used in medical certificates when psoriasis justifies work leave or functional limitations. Documentation should specify how the condition impacts work capacity, particularly in cases of palmoplantar psoriasis that hinders manual activities, erythrodermic psoriasis that causes systemic debilitation, or during severe exacerbations. Certificates for medical follow-up, phototherapy administration, or injectable medication administration should also include the appropriate code. Precise coding facilitates understanding of the condition by employers and social security systems.

Is psoriasis contagious? No, psoriasis is absolutely not contagious. It is a genetically determined autoimmune disease, where the immune system erroneously attacks healthy skin cells, causing epidermal hyperproliferation. There is no transmission through physical contact, sharing personal objects, or proximity to affected individuals. This information is crucial to combat the social stigma frequently faced by patients. Education of family members, colleagues, and the general public about the non-infectious nature of psoriasis contributes significantly to patients' psychosocial well-being.

What factors can trigger or worsen psoriasis? Multiple factors can trigger or exacerbate psoriasis in genetically predisposed individuals. Emotional stress is a common trigger, often preceding flares. Infections, particularly streptococcal pharyngitis, can trigger guttate psoriasis especially in young people. Skin trauma (Koebner phenomenon) causes lesion appearance in areas of mechanical injury. Medications such as beta-blockers, lithium, antimalarials, and nonsteroidal anti-inflammatory drugs can induce or aggravate psoriasis. Excessive alcohol consumption and smoking are associated with worse disease control. Cold and dry climate tends to worsen symptoms, while moderate sun exposure generally improves lesions.

Is there a relationship between psoriasis and other diseases? Yes, psoriasis is significantly associated with multiple systemic comorbidities. Up to 20% of patients develop psoriatic arthritis, a potentially disabling articular inflammatory condition. There is strong association with components of metabolic syndrome, including obesity, type 2 diabetes, hypertension, and dyslipidemia. Patients with psoriasis present increased cardiovascular risk, with higher incidence of myocardial infarction and cerebrovascular accident. Psychological disorders, especially depression and anxiety, are significantly more prevalent. Inflammatory bowel disease, particularly Crohn's disease, also shows epidemiological association. Optimal management requires a multidisciplinary approach considering these comorbidities.

Can children develop psoriasis? Yes, although less common than in adults, psoriasis can manifest in childhood, including in infants. Pediatric psoriasis frequently presents as guttate psoriasis, especially after respiratory infections. Involvement of the diaper area (napkin psoriasis) is a characteristic form in infants. Children may experience significant psychosocial impact due to stigma and bullying. Pediatric treatment requires special considerations regarding the safety of systemic medications, with preference for topical therapies and phototherapy when appropriate. Multidisciplinary follow-up including pediatric dermatologist and psychological support is fundamental to optimize outcomes and quality of life.

Conclusion:

Appropriate coding of psoriasis using the EA90 code from ICD-11 is essential for accurate clinical documentation, epidemiological research, and appropriate management of this complex and prevalent dermatological condition. Understanding when to apply this code, differentiating it from similar conditions, and properly documenting specific clinical characteristics enables better patient care and contributes to advances in knowledge and treatment of this chronic disease that significantly impacts the quality of life of millions of people globally.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Psoriasis

Partager